SynthesisHuman vaccines & immunotherapeutics2026
The relative immunogenicity of 20-valent and 15-valent pneumococcal conjugate vaccines: A systematic review and network meta-analysis.
Synthesis in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- The relative immunogenicity of 20-valent and 15-valent pneumococcal conjugate vaccines: A systematic review and network meta-analysis.Human vaccines & immunotherapeutics · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Higher-valent pneumococcal conjugate vaccines (PCV) may reduce adult pneumococcal disease, but no head-to-head trials compare PCV20 vs. PCV15 in adults. We synthesized serotype-specific immunogenicity from randomized controlled trials using a network meta-analysis via the common comparator PCV13. PubMed, Scopus, Cochrane Library, and ClinicalTrials.gov were searched for trials enrolling adults (≥18 y) and evaluating PCV20 or PCV15. The primary endpoint was opsonophagocytic activity (OPA) geometric mean titers (GMTs) at 30 d, summarized as ratios of means on the log scale. Heterogeneity/inconsistency were assessed and prespecified age-stratified analyses were performed where possible. Seventeen trials met inclusion criteria but nine contributed OPA data for 15 serotypes. Across most shared serotypes, PCV20 elicited comparable or lower OPA responses than PCV15, with significantly higher responses for PCV15 for several serotypes, including 3. PCV20 exceeded PCV15 only for serotype 4. Age-stratified results suggested greater relative advantages for PCV15 in older adults. Direct comparative and real-world effectiveness studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.